Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation - A report of the US Multicenter Liver Study Group TRANSPLANTATION Sher, L. S., Cosenza, C. A., Michel, J., Makowka, L., Miller, C. M., Schwartz, M. E., Busuttil, R., McDiarmid, S., Burdick, J. F., Klein, A. S., Esquivel, C., Klintmalm, G., Levy, M., Roberts, J. P., Lake, J. R., Kalayoglu, M., DALESSANDRO, A. M., Gordon, R. D., Stieber, A. C., Shaw, B. W., Thistlethwaite, J. R., Whittington, P., Wiesner, R. H., Porayko, M., Bynon, J. S., Eckhoff, D. E., Freeman, R. B., Rohrer, R. J., Lewis, W. D., Marsh, J. W., Peters, M., Powelson, J., Cosimi, A. B. 1997; 64 (2): 258-263

Abstract

A study was performed by 17 different U.S. liver transplantation centers to determine the safety and efficacy of conversion from cyclosporine to tacrolimus for chronic allograft rejection.Ninety-one patients were converted to tacrolimus a mean of 319 days after liver transplantation. The indication for conversion was ongoing chronic rejection confirmed by biochemical and histologic criteria. Patients were followed for a mean of 251 days until the end of the study.Sixty-four patients (70.3%) were alive with their initial hepatic allograft at the conclusion of the study period and were defined as the responder group. Twenty-seven patients (29.7%) failed to respond to treatment, and 20 of them required a second liver graft. The actuarial graft survival for the total patient group was 69.9% and 48.5% at 1 and 2 years, respectively. The actuarial patient survival at 1 and 2 years was 84.4% and 81.2%, respectively. Two significant positive prognostic factors were identified. Patients with a total bilirubin of < or = 10 mg/dl at the time of conversion had a significantly better graft and patient survival than patients converted with a total bilirubin > 10 mg/dl (P=0.00002 and P=0.00125, respectively). The time between liver transplantation and conversion also affected graft and patient survival. Patients converted to tacrolimus < or = 90 days after transplantation had a 1-year actuarial graft and patient survival of 51.9% and 65.9%, respectively, compared with 73.2% and 87.7% for those converted > 90 days after transplantation. The mean total bilirubin level for the responder group was 7.1 mg/dl at the time of conversion and decreased significantly to a mean of 3.4 mg/dl at the end of the study (P=0.0018). Thirteen patients (14.3%) died during the study. Sepsis was the major contributing cause of death in most of these patients.Our results suggest that conversion to tacrolimus for chronic rejection after orthotopic liver transplantation represents an effective therapeutic option. Conversion to tacrolimus before development of elevated total bilirubin levels showed a significant impact on long-term outcome.

View details for Web of Science ID A1997XN86900014

View details for PubMedID 9256184